ʻO Liprimar 10 papa, 20 mg: nā ʻōlelo a me nā loiloi i ka lāʻau lapaʻau

Loaʻa i ka ʻenemi MUSHROOM hoʻohiki E hoʻomaʻemaʻe ʻia kou mau kui i nā lā 3! Lawe ia.

Pehea e hiki wawe ai i ka hoʻoneʻe ʻana i ka ikaika arterial ma hope o 40 makahiki? Maʻalahi ka ʻano ʻaʻai, kākau i lalo.

ʻEha ʻoe i nā ʻōpū hemorrhoids? Aia kahi ala i waho! Hiki ke ho'ōla ia ma ka home i kekahi mau lā, pono ʻoe.

E pili ana i ka loaʻa ʻana o nā pōpoki mai ka ODOR mai ka waha! I kahi lā, inu ʻoe i ka wai me kahi pāhaʻi ..

Nā hopena hopena

Hiki paha nā hopena ʻino:

• Hematopoietic ʻōnaehana: luhi - thrombocytopenia,
• Pūnaehana pīhoihoi waena: pilikia o ka ʻōpū, ka ʻōpū, ka hopena o ka maʻi asthenic,
• Pūnaehana digestive: pinepine - ʻeha o ka ʻōpū, ʻiliʻī, dyspepsia, nausea, ke nānā ʻana, constipation, i ʻole nā ​​loi - hoʻopuka, jaundice cholestatic, pancreatitis, hepatitis, anorexia,
• Nā hui kūloko: nā ʻili o ka ʻili, ke kaulua, ka pruritus, urticaria, erythema multiforme, ke ʻano anaphylactic, ʻehā a me ka epacmalsis epidermal,
• Pūnaehana musculoskeletal: pinepine - myalgia, ʻaʻole liʻiliʻi - myositis, nā mākala o ka naʻau, myopathy, rhabdomyolysis, ʻeha hoʻi, arthralgia,
• Metabolism: hyperglycemia, hypoglycemia, hoʻonui i nā kiʻekiʻe o ka serum creatine phosphokinase,
• ʻO kekahi: paʻakikī - nā ʻehaʻeha, ka impotence, hoʻonui i ka momona, ka nui o ka momona, tinnitus, alopecia, ka hopena o ka renal lua, ka edema peripheral.

Basically, ke hoʻomanawanui maikaʻi ʻia ka lāʻau lapaʻau. ʻO nā hopena o ka ʻaoʻao, inā hele mai lākou, he mau liʻiliʻi liʻiliʻi a me kahi ʻano transient. Inā loaʻa iā ʻoe nā nāwaliwali o ka mākala a i ʻole ka hoʻāʻo e hōʻike ʻole, ka hele pū me ka maʻi a me ka malaise paha, makemake koke ka mea maʻi e ʻike i ke kauka.

Nā kuʻina o Liprimar

Hoʻololi nā kumu hoʻohālike o ka waiwai ikaika:

• Anvistat
• Hoʻokahi
• Atomax
• Ator
• Atorvastatin
• Atorvox
• Hana ʻia
• Kāleka
• Lipona
• Lipoford
• Lipumelie,
• Novostat,
• Kauka
• Torvacard
• Torvalip
• Kauka
• Tulip.

Nānā: pono ke ʻae ʻia ka hoʻohana ʻana o nā analogues a me ke kauka hele mai.

ʻO ke kumukūʻai kūpono o LIPRIMAR, nā papa i loko o nā lāʻau lapaʻau (Moscow) ʻo 730 mau rubles.

Nā kumu kūʻai no ka lypimar i loko o nā lāʻau lapaʻau ma Moscow

Hōʻikeʻike a nā kauka e pili ana i ka lypimar

Hoʻohana wau i ka Liprimar kumu me ka hopena ikaika i ka mālama ʻana i nā maʻi erectile i kumu ʻia e ka atherosclerosis, dyslipidemia. Ma hope o kekahi mau mahina o ka lawe ʻana i nā hopena maikaʻi e ʻike ʻia. ʻO ka lānai haʻahaʻa e 20 mg i kēlā me kēia lā. ʻO ka nānā ʻikepili ʻana i ka lawelawe lipid! ʻO ka waiwai maikaʻi loa no ke kālā.

ʻO ka pono no kahi lōʻihi lōʻihi, maʻamau mau, hoʻokomo ʻia. ʻO ka ulu ʻana o ka ulu ʻana o ka puʻuwai, hiki ke kaumaha. I nā hanana pinepine - ulu ʻole ke ʻano o ka hōʻailona ma ka neʻe ʻana. Akā e hoʻomaopopo pono ia ka hopena o ka hopena i ka liʻiliʻi ma lalo o ka 1% o nā hihia o Liprimar.

Pono kekahi ʻike e pili ana i ka hana me ka pathophysiological e hele mai nei: kahi i hoʻopili ʻia ai kahi ʻoki i ka atherosclerosis e pili wale ana me ka hemo ʻana o ka kaila - huʻi ʻana i ka penis ma o nā kīʻaha koko, akā pū kekahi me ka pohō o ka testicle, kahi i hoʻokumu ʻia ai ka nui o ke kāne male hormon, testosterone.

Loaʻa nā hopena ʻaoʻao. Loaʻa nā pilikia me nā enzyme hepatic. ʻAʻohe hihia o ka hui pū me ka maʻi diabetes i kaʻu hoʻomaʻamaʻa.

ʻO Atorvastatin kahi hana a me ka palekana, e noʻonoʻo ana i ka hana pono nui, ka lio o ka cardiology o kēia manawa. ʻO ka dosis hana he 20-40 mg i kēlā me kēia lā, keu nui me nā mea maʻi me ka maʻi ʻalihi coronary i hōʻoia ʻia. Hiki ke hoʻohana ʻia kahi nui o 80 mg ma ke ʻano hemo nui e hoʻokūpaʻa ʻia i ka pōkole ma nā mea maʻi me ACS. Ke noi ikaika nei au i nā hoa hana ʻaʻole e hoʻohana i nā ʻōlelo aʻoaʻo utopian ma ka hoʻohana ʻana i nā dosis kiʻekiʻe o ka atorvastatin maʻamau. ʻAʻole hoʻohālikelike ʻia ka hopena o kēia ala, a ua hoʻāla ka palekana i nā nīnau he nui. I ka nui o nā kūlana kulekele, ʻoioror ʻoi aku ka mea ma ka rosuvastatin i kāna ʻike palekana.

Hoʻopā ʻia e ka poʻe me ka lāʻau lapaʻau, kahi inoa maʻalahi a me ka poina ʻole ʻaʻole cumbersome inoa.

No ka manawa lōʻihi ʻaʻole hiki iaʻu ke hoʻomaopopo i ke kumu ʻaʻole hiki iaʻu ke hoʻohana maʻalahi i ka Atorvastatin ma mua, i ka hopena o ka noi.

Ua aʻo hou au e pili ana i kēia lāʻau lapaʻau, akā ma ka hana noʻu wau i noho i kekahi o nā wahi nui i ka mana o ka tofiga.

ʻO Liprimar ʻo ia ka atorvastatin kumu o ka ʻoihana Pfizer. Ua loaʻa iā ia ka nui o nā haʻawina e hōʻike ana i kona hopena therapeutic: e hōʻemi i ka hopena o ka maʻi myocardial infarction, stroke, mortally from kumu cardiovascular a me ka make maʻamau. ʻO kaʻoiaʻiʻo, ua emi ka nui o kēia mau hanana i ka poʻe i loaʻa kahi maʻi mua mua loa - ke ala ʻia nei mai ka maʻi ʻalopona coronary, me ka poʻe me ka nui o nā mea kūlohelohe nui: kolamu kiʻekiʻe, kiʻekiʻe koko, maʻi maʻi, ʻokiʻoki, etc.

E like me nā mea a pau.Ke kū nei nā hemahema i ka wā i hikiʻole ai nā manaʻo kūponoʻole. ʻAʻole makemake wau i ka ʻike ʻana o ka pāpākiʻo i kahi hoʻolaha hōʻino e "hoʻolaha" a "expose" statins me kahi nui o ka nonsense a me nā fables. ʻAʻole "luku" ʻo nā ʻōlelo kuʻuna a ʻaʻole nā ​​puʻuwai a me nā ʻōpū, ʻaʻole hoʻi e hōʻeha i ka maʻi Alzheimer a i ʻole ka maʻi kanesa. ʻO nā statins kekahi o nā mea i aʻo ʻia a palekana maikaʻi loa i ka mōʻaukala o ka lāʻau lapaʻau.

Hiki i ka mea nāna e ʻae iā Liprimar e like me ka lāʻau o ka atorvastatin hiki iā ia ke lawe iā Liprimar i mea maʻamau. Inā ʻaʻohe kālā no ka hoʻokipa o ka lā lōʻihi o Liprimar, hiki iā ʻoe ke lawe i nā kuʻuna, akā nā mea kiʻekiʻe. ʻO Atoris kekahi o lākou.

ʻO ka lāʻau kanu mua mai ka hui o statins (atorvastatin). E hōʻemi maikaʻi ia LDL. Hoʻonohonoho ʻia e ke kauka e like me nā hōʻike ʻana, me ka mālama ʻana i ka pilikia cardiovascular.

Hiki ke hoʻonui nui i ke kiʻekiʻe o ka transaminases, ka pilina me ka mana o ALT, kahi AST i ka dinamika e pono ai. Ua manaʻo ʻia e lawe ʻia ka lāʻau lapaʻau ma ke kiʻekiʻe o ALT, AST a hiki i 3 mauʻano maʻamau.

Me ka hoʻohana mau ʻana, hoʻemi ka nui o ka stenosis, loiloi kūʻokoʻa ma o ka ultrasound. Aneane ʻaʻole hoʻopiʻi. He kumu kūpono ke kumukūʻai me ke kāleka inā lawe ʻoe i kahi ʻāpana nui. Kūleʻa wau e like me ka atorvastatin maikaʻi loa.

Ke hoʻomaopopo nei au iā ia i nā maʻi āpau, ʻoiaʻiʻo, inā he mea kūʻai aku - ke ʻimi nei au i kahi ʻano like ʻole.

Hoʻomaʻaʻe! Me nā papa poli, ma hope o 3 mau mahina hiki ke hoʻemi i ka pakeneka o ka stenosis ICA, nā haʻahaʻa subclavian e 10-20%!

Kūʻai, akā no ka huahana huahana hikiʻole ke hana me nā mea liʻiliʻi. ʻIke ʻia nā mea a pau i ka hoʻohālikelike - me nā rosuvastatin, ʻoi aku ka nui o nā mea kūʻai aku ma mua o ka liprimar maʻamau.

No kāu poʻe aloha - ʻo ia ka lāʻau o ke koho!

Lapaʻau

ʻO ka lipid-liping Synthetic lāʻau. ʻO Atorvastatin he mea mālama i ka hoʻokūkū koho o ka HMG-CoA reductase, he kīme nui e hoʻohuli ana i ka 3-hydroxy-3-methylglutaryl-CoA i mevalonate, kahi mea i mua i ka lāʻau, a me ka kolamu.

I nā mea maʻi me ka homozygous a heterozygous familial hypercholesterolemia, nā non-familial o kahi o ka hypercholesterolemia a me ka dyslipidemia i hui pū ʻia, ka atorvastatin hōʻemi i ka kolamu piha (Ch) i loko o ka plasma, kolesterol-LDL a me ka apolipoprotein B (apo-B), a i kumu ʻole pū kekahi me ka Chr-LH i hoʻonui nui ʻia o HDL-C.

Hoʻopili ke Atorvastatin i ka hoʻoneʻe ʻana o ka kolamu a me nā lipoproteins i loko o ke koko koko, e hoʻoneʻe ana i ka hoʻōla ʻana o HMG-CoA a me ka synthesis o ka kolamu o ka ate a me ka hoʻonui ʻana i ka nui o nā mea hoʻokipa LDL hepatic ma luna o ka pūlaka, kahi e hoʻonui ai i ka hoʻonui a me ka catabolism o LDL-C.

Hoʻopili ke Atorvastatin i ka hoʻokumuʻana o LDL-C a me ka nui o nā māhele LDL. Hoʻokumu ia i ka hoʻonui i hoʻomau a hoʻomau i ka hana o nā mea LDL e komo pū ai, a hui pū me nā loli qualitative maikaʻi loa i nā hapa LDL. Hoʻēmi i ka pae o ka LDL-C i nā mea maʻi me ka hypercholesterolemia homozygous me ka pale ʻana i ka lāʻau lapaʻau me nā lāʻau lapaʻau ʻē aʻe.

I ka mālamaʻana o Atorvastatin i nā wai o 10-80 mg e hoʻemi i ka pae o ka kolamu o ka nui o ka 30-46%, LDL-C e 41-61%, apo-B e 34-50% a me TG e 14-33%. Hoʻohālike nā hopena lapaʻau i nā mea maʻi me ka heterzygous famamial hypercholesterolemia, ʻaʻohe ʻohana ʻohana o hypercholesterolemia a me ka hyperlipidemia i hui pū ʻia, me ka komo pū i nā mea maʻi me ka diabetes-mellitus-non-diabetes mellitus.

I nā maʻi me ka hypertriglyceridemia hoʻokaʻawale, hōʻemi loa ʻo atorvastatin i ka kolamu a pau, Chs-LDL, Chs-VLDL, apo-B a me TG a hoʻonui i ke kiʻekiʻe o Chs-HDL. I nā maʻi me ka dysbetalipoproteinemia, hōʻemi ke kolamu i ka lipoproteins density intermediate.

I ka poʻe maʻi me ka type IIa a me IIb hyperlipoproteinemia e like me ka helu ʻana o Fredrickson, ʻo ka nui o ka piʻi ʻana o ka hoʻonui ʻana o HDL-C i ka wā mālama me ka atorvastatin (10-80 mg), i hoʻohālikelike ʻia me ka waiwai mua, ʻo ia ka 5.1-8.7% a ʻaʻole i hilinaʻi ma ka ʻōlelo. Aia ka nui o ka hoʻoliʻiliʻi a hilinaʻi nui i ka pae: ʻo ka kolamu piha / Chs-HDL a me Chs-LDL / Chs-HDL e ka 29-44% a me 37-55%, ia manawa.

ʻO Liprimar ® ma kahi o 80 mg e hoʻohaʻahaʻa nui loa i ka hōʻemi o ka hoʻopiʻi ischemic a me ka make ma 16% ma hope o kahi papa 16 wiki, a me ka hopena o ka hoʻoliʻi hou ʻana no ka angina pectoris, i hui pū ʻia e nā hōʻailona o ka ischemia myocardial, e 26%. I nā mea maʻi me nā pae baseline like ʻole o ka LDL-C, Liprimar ® hōʻemi i ka hopena o ka hoʻopiʻi ischemic a me ka make (i nā mea maʻi me ka myocardial infarction me ka hawewe Q a me ka pupule paʻa ʻole, nā kāne a me nā wahine, nā mea maʻi ma lalo o ke ola o 65 mau makahiki).

ʻO ka emi ʻana o nā pae plasma o LDL-C ka mea i ʻoi aku me ka maikaʻi o ka lāʻau lapaʻau ma mua o kona hoʻomoʻa ʻia i ka plasma koko.

Loaʻa ka hopena therapeutic i 2 mau pule ma hope o ka hoʻomaka ʻana o ka hōʻola, a hiki i ka nui loa ma hope o 4 mau hebedoma a hoʻomau i ka holoʻokoʻa o ka wā mālama.

Kāohi pilikia Cardiovascular

I ka noi ʻana o Anglo-Scandinavian o ka hoʻopiʻi o ka maʻi cardiovascular, ʻoi aku ka hopena o ka lipid-hoʻohaʻahaʻa (ASCOT-LLA), ua ʻike ʻia ka hopena o ka atorvastatin ma ka maʻi ʻeha a me ka mea make i loko o ka puʻuwai, a ua ʻike ʻia ka hopena o ka hopena atorvastatin ma ke ʻano o ka 10 mg nui ka nui o ka hopena o ka plasebo, a no laila ua hoʻoholo ʻia. ka hoʻomaka mua o ke aʻo ʻana ma hope o 3.3 mau makahiki ma mua o nā makahiki he 5 i manaʻo ʻia.

Ua hoʻemi nui ʻia ʻo Atorvastatin i ka hoʻomohala ʻana o nā hoʻopiʻi hou aʻe nei:

ʻAʻole i loaʻa ka emi nui o nā hōʻailona o ka maʻi maʻamau a me ka make ma nā kumu cardiovascular, ʻoiai aia nā kūpono kūpono.

I ka hui pū ʻana o ka hopena o ka atorvastatin i nā mea maʻi me ka maʻi diabetes mellitus type 2 (CARDS) i ka hopena hōʻeha a me ka mea ʻole ke make o nā maʻi cardiovascular, hōʻike ʻia ʻo ia ka mālama ʻana me ka atorvastatin, ka manaʻo ʻole o ke kāne maʻi, ʻokoʻa, a i ʻole pae o LDL-C, hoʻemi i ka pilikia o ka hoʻomohala ʻana i nā maʻi cardiovascular e hiki mai ana. :

I loko o ka noiʻi ʻana i ka hoʻomohala ʻana o ka atherosclerosis coronary me ka ʻeha hypolipidemic therapy (REVERSAL) me ka atorvastatin ma kahi pākēpē o 80 mg i nā mea maʻi me ka maʻi ʻalihi coronary, ʻike ʻia ka nui o ka hoʻemi ʻana o ka nui o ka atheroma (ka hapa mua o ka hoʻomaʻamaʻa) mai ka hoʻomaka ʻana o ka noi ʻana he 0.4%.

Ma ka Intensive Cholesterol Reduction Program (SPARCL) ʻike i ka atorvastatin ma kahi maʻa o 80 mg / lā i hōʻemi ʻia ka hopena o ka hōʻeha hou ʻana a i ʻole ka make i ka maʻi maʻi i loaʻa ka mōʻaukala o kahi hōʻeha a i ʻole ka neʻe ʻana i ka ischemic attack me ka maʻi ʻeha coronary e ka 15% hoʻohālikelike ʻia me ka placebo. I ka manawa like, ua hoʻemi nui ʻia ka loaʻa ʻana o ka hōʻeha o nā ʻōkuhi a me ka hōʻola hou aku i nā loiloi. ʻO ka hōʻemi ʻana i ka hopena o ka maʻi cardiovascular i ka wā o ka lapaʻau me ka atorvastatin i nānā ʻia i loko o nā hui āpau koe wale nō ka mea i komo i nā mea maʻi me ka maʻi hemorrhagic mua a i ʻole (7 i ka hui atorvastatin ma 2 i ka hui pletebo).

I loko o nā mea maʻi i mālama ʻia me ka hopena atorvastatin ma ke ʻano o 80 mg, i ka loaʻa ʻana o ka hemorrhagic a i ʻole ischemic stroke (265 ma mua o 311) a i ʻole IHD (123 kūmole 204) ka liʻiliʻi ma mua o ka pūʻulu mana.

Kākoʻo pale ʻelua o nā pilikia hoʻonā

Ma nā ʻōlelo o ka New Target Study (TNT), ua hoʻohālikelike ʻia nā hopena o ka atorvastatin ma nā papa o 80 mg / lā a me 10 mg / lā ma ka hopena e hoʻomohala ana i nā hoʻopiʻi cardiovascular ma nā maʻi me nā maʻi maʻi neʻe i hōʻoia ʻia e nā maʻi.

Atorvastatin ma ke ʻano o 80 mg hoʻohaʻahaʻa nui ʻia ka hoʻomohala ʻana o kēia mau ʻōlelo hoʻopiʻi:

E hoʻokuʻu i ke ʻano

ʻO nā papa papaʻa, i hui ʻia me ka uhi ʻia o ke kiʻi keʻokeʻo, he elliptical, i kahakaha me "10" ma ka ʻaoʻao a me ka "PD 155" ma ka ʻaoʻao, ma ka palahalaha kekahi maʻa keʻokeʻo.

Nā mea hoihoi: calcium carbonate - 33 mg, microcrystalline cellulose - 60 mg, lactose monohydrate - 32.8 mg, sodium croscarmellose - 9 mg, polysorbate 80 - 0.6 mg, hyprolose - 3 mg, magnesium stearate - 0.75 mg.

ʻO ka mana o nā pāpale kiʻi: opadry keʻokeʻo YS-1-7040 (hypromellose - 66.12%, polyethylene glycol - 18,9%, titanium dioxide - 13.08%, talc - 1.9%) - 4.47 mg, simethicone emulsion (simethicone - 30%, stearic emulsifier - 0,075% , ka waiū sorbic, ka wai) - 0,03 mg, keena kukui - 0,08 mg.

10 kamepiula - blisters (3) - nā ʻeke pepa.
10 kamepiula - nā kāmela (10) - nā ʻeke pepa.

Ma mua o ka hoʻomaka ʻana i ka mālama ʻana me Liprimar ®, pono e hoʻāʻo e hoʻokō i ka hoʻomehana o ka hypercholesterolemia ma o kaʻaiʻai, ka hoʻomaʻamaʻa ʻana a me ka pohō o ke kaumaha i nā mea maʻi me ka huelo, me ka mālama ʻana i ka maʻi lalo.

Ke hoʻoholo nei i ka lāʻau lapaʻau, pono ke hoʻomau i ka mea maʻi i kahi meaʻai hypocholesterolemic maʻamau, pono ia e hahai i ka wā o ka mālama ʻana.

Lawe ʻia ka lāʻau lapaʻau i kēlā me kēia manawa o ka lā, me ke ʻano o ka komo ʻana o ka meaʻai.

Hoʻololi ʻia ka ʻano o ka lāʻau lapaʻau mai ka 10 mg a 80 mg 1 ka manawa / lā, e lawe ʻia ke koho ʻana i ka ʻikepili me ka noʻonoʻo ʻana i ka ʻike mua o ka LDL-C, ke kumu o ka hoʻomohala a me ka hopena pilikino. ʻO ka nui loa ka 80 mg 1 mau lā / lā.

I ka hoʻomaka ʻana o ka hoʻōla a me / a i ka manawa o ka hoʻonui ʻana i ka mahele o ka liprimar ®, pono ia e nānā i ka maʻi lipid plasma ma kēlā me kēia mau hebedoma 2-4 a e hoʻoponopono pono i kēia ʻano.

Ma ka maʻamau o ka hypercholesterolemia a me ka hoʻohui (hoʻohui ʻia) i ka hyperlipidemia no ka hapa nui o nā maʻi, ʻo ka nui o nā liprimar he 10 mg 1 manawa / lā. Hōʻike ʻia ka hopena therapeutic i loko o 2 mau pule a hiki i ka lōʻihi ma waena o 4 mau pule. Me ka lōʻihi o ka mālama ʻana, hoʻomau ka hopena.

Me ka hypercholesterolemia famerial homozygous, ua kuhikuhi ʻia ka lāʻau lapaʻau ma ka maʻa o 80 mg 1 mau manawa / lā (kahi hōʻemi i ka pae o LDL-C e ka 18-45%).

I ka hihia o ka paleka o ka ate, pono e hoʻemi ʻia ka nui o ka liprimar ® ma lalo o ka mālama mau ʻana i ka hana a ACT a me ka hana ALT.

ʻAʻole pili ka hana o ka renal i ka pale ʻana i ka ʻike o ka atorvastatin i loko o ke kaila koko a i ʻole ka pae o ka hōʻemi i loko o ka ʻike o LDL-C i ka wā e hoʻohana ai i Liprimar, no laila, ʻaʻole pono ka hoʻoponopono ʻana o ka lāʻau.

I ka wā e hoʻohana ai i ka lāʻau lapaʻau i nā mea maʻi ma waena o nā kānaka, nā ʻokoʻa o nā hopena a me ka palekana i hoʻohālikelike ʻia me ka lehulehu mahele ʻaʻole i loaʻa, ʻaʻole koi ʻia ka hoʻoponopono ʻana.

Inā pono, e hoʻohana ʻia ka hoʻohana me ka cyclosporine, ʻaʻole pono ka nui o ke aniani o Liprimar ® i 10 mg.

Nā manaʻo e hoʻoholo ai i ke kumu o ka mālama ʻana

A. Noha mai ka National NCEP Cholesterol Education Program, USA

Me ka hoʻomohala like ʻana o Liprimar a me kahi kōnao i loaʻa i ka magnesium a me nā hydroxides alumini, ua emi iho ka ʻike o ka atorvastatin i ka plasma e pili ana i ka 35%, akā naʻe, ʻaʻole i loli ka nui o ke kahe o ka pae o LDL-C.

Me ka hoʻohana like ʻana o Liprimar ® ʻaʻole i hoʻopilikia i ka pharmacokinetics o phenazone, no laila, ʻaʻole ka manaʻo ka launa pū me nā lāʻau ʻē aʻe e like me ka cytochrome isoenzymes.

Me ka hana like o colestipol, hoʻemi ʻia ka nui o ka atorvastatin i ka plasma e pili ana i 25%. Eia nō naʻe, ʻoi aku ka hopena o ka lipid-hoʻemi ʻana i ka hui o ka atorvastatin a me colestipol i kēlā me kēia pālolo.

Me ka hoʻohana hou ʻana o ka digoxin a me Liprimar ma kahi o 10 mg, ʻaʻole i loli ka manaʻo o ke kūkaʻi o ka digoxin i loko o ke kahe koko. Eia nō naʻe, i ka mea i hoʻohana ʻia ka digoxin i hui pū ʻia me Liprimar ma kahi hapa o 80 mg / lā, hoʻonui ʻia ka ʻike o ka digoxin ma kahi o 20%. ʻO nā maʻi e loaʻa ana i ka digoxin i hui pū ʻia me Liprimar e pono ai ka nānā ʻana ma ka lāʻau.

Me ka hoʻohana like ʻana o Liprimar ma kahi o 10 mg 1 mau lā / lā a me azithromycin ma kahi wai o 500 mg 1 manawa / lā, ʻaʻole i loli ka ulu ʻana o ka atorvastatin i ka plasma.

Me ka hana like o Liprimar a me kahi ulu o ka waha e loaʻa ana i ka norethisterone a me ka ethinyl estradiol, he nui nui ka nui o ka AUC o norethisterone a me ka ethinyl estradiol i nānā ma kahi o 30% a 20%, kekahi. Pono e noʻonoʻo ʻia kēia hopena ke koho ʻana i kahi contraceptive ā waha no ka wahine e loaʻa ana i ka Liprimar ®.

ʻAʻole he hopena koʻikoʻi o Liprimar ® me ka hoʻohana like ʻana i ka pharmacokinetics o terfenadine.

ʻAʻole i ʻike ʻia nā ʻano hōʻailona o kahi pilina koʻikoʻi pili i ka atorvastatin me warfarin.

Me ka hana like o Liprimar ma kahi o nā memo o 80 mg a me amlodipine ma ke ʻano o ka nui o 10 mg, ʻaʻole i loli ka hopena o nā pharmacokinetics o atorvastatin i ka kūlike.

Hoʻololi hou

Ma nā haʻawina loiloi, ua hoʻohana ʻia ʻo Liprimar ® me ka hoʻohui me nā lāʻau antihypertensive a me nā estrogens, i kuhikuhi ʻia i ka hoʻololi ʻana, ʻaʻohe ʻano pili i ʻole e pili ana i nā hōʻailona pili maʻi. ʻAʻole i mālama ʻia nā noi ʻana o nā mea pili me nā lāʻau lapaʻau kūikawā.

ʻŌpū a me ka lactation

Hoʻopili ka Liprimar ® no ka hoʻohana ʻana i ka wā hāpai a ma ka wā lactation (ka umauma maʻi).

Pono nā wahine o nā makahiki hānau hānau i nā ala kūpono o ka contraception i ka wā mālama. Hiki ke kaukaʻi ʻia ʻo Liprimar ® i nā wahine o ka hānau ʻana inā he haʻahaʻa loa paha ka hiki ʻana o ka hapai, a haʻi ʻia ka mea maʻi e pili ana i ka hiki ʻana mai i ka pūpū i ka wā mālama.

ʻAʻole i ʻike ʻia inā excreted i ka atorvastatin i loko o ka waiū umauma. Inā pono e hoʻohana i ka lāʻau lapaʻau i ka wā lactation, pono nā hōʻuluʻulu ʻana i mea e pale ai i ka pale o nā hanana hōʻino.

Hoʻohana no ka hana lawelawe lēwa

Ua hoʻohana ʻia ka hoʻohana ʻana i ka lāʻau lapaʻau ma muli o nā maʻi ʻoi aku ka maʻi a me ka hoʻonui ʻana ma ka hana serum o nā transaminases (ʻoi aku paha ma mua o 3 mau manawa i hoʻohālikelike ʻia me VGN) o kahi kumu ʻike ʻole.

I ka hihia o ka paleka o ka ate, pono e hoʻemi ʻia ka nui o ka liprimar ® ma lalo o ka mālama mau ʻana i ka hana a ACT a me ka hana ALT.

Me ka mālama aka, pono e kuhikuhi ʻia ka lāʻau inā inā he mōʻaukala o ka maʻi ʻōʻai.

Nā ʻōlelo kikoʻī

Ka hana i luna

E like me nā lāʻau lapaʻau lipid-haʻahaʻa o ka papa like, ma hope o ka mālamaʻana me Liprimar ®, kahi maʻi (e ʻoi aku ka 3 manawa i hoʻohālikelike ʻia me VGN) hoʻonui i ka hana serum o AST a me ALT. ʻO ka hoʻonui pinepine mau i ka pae serum o nā transaminases hepatic (ʻoi aku ma mua o 3 mau manawa i hoʻohālikelike ʻia me VGN) i nānā ʻia ma 0.7% o nā mea maʻi e loaʻa ana i ka Liprimar ® i nā hoʻokolohua lapaʻau. ʻO ka pinepine o nā loli i ka wā e hoʻohana ai i ka lāʻau lapaʻau ma nā inika o 10 mg, 20 mg, 40 mg a me 80 mg o 0.2%, 0.2%, 0.6% a me 2.3%, kēlā me kēia. I ka piʻi pinepine ʻana o ka hana hepatic transaminase maʻamau ʻaʻole i mālama ʻia e ka jaundice a i ʻole nā ​​hōʻike olakino ʻē aʻe. Me ka hoʻohaʻahaʻa ʻana i ka hopena o Liprimar ®, ka wā ʻole a me ka wehe ʻole ʻana o ka lāʻau, ke ʻano o ka transaminases hepatic i kona pae mua.Hoʻomau ka hapa nui o nā poʻe maʻi e lawe i ka Liprimar ® i kahi hoʻemi haʻahaʻa ʻole nā ​​hopena lāʻau lapaʻau.

Ma mua o ka hoʻomaka ʻana, 6 mau hebedoma a me 12 mau pule ma hope o ka hoʻomaka ʻana o ka lāʻau lapaʻau a ma hope paha o ka hoʻonui ʻana i ka nui o ka huaʻōlelo, ʻoiai ma ka papa holoʻokoʻa o ka mālama ʻana, pono ia e nānā i nā ʻōnaehana hana pili. E nānā pū ʻia ka hana naʻau inā ʻike ʻia nā hōʻailona koʻikoʻi o ka hōʻeha o ka puʻuwai. I ka nui o ka hoʻonui ʻana i nā hana o ka transaminases hepatic, pono e nānā ʻia kā lākou hana a hiki i ka hoʻonui ʻia. Inā ulu ka hoʻonui i ka hana o AST a i ʻole ALT e ka nui o nā manawa he 3 i hoʻohālikelike ʻia me VGN e hoʻomau nei, e pono ana e hōʻemi i ka hopena a i ʻole ke kahuli ʻana iā Liprimar ®.

He hana huapili o nā iwi

I nā poʻe maʻi e loaʻa ana i ka Liprimar ®, ua ʻike ʻia ka myalgia. ʻO ka hōʻike ʻana i ka myopathy (ʻo ka hōʻeha o ka ʻōpū a me nā nāwaliwali i hui pū me ka hoʻonui ʻana i ka hana CPK ma o ka 10 mau manawa i hoʻohālikelike ʻia me VGN) pono e manaʻo ʻia i nā mea maʻi me ka diffal myalgia, ʻeha naʻau a nāwaliwali a / a i ʻole he mākaukau e hoʻonui i ka hana CPK. Pono e hoʻokuʻu ʻia ka hopena o ka liprimar ® ma kahi o ka hoʻonui ʻia ʻana o ka hana CPK, ma ke alo o ka myopathy i hoʻopaʻa ʻia a i ʻole. I ka piʻi ʻana o ka manaʻo myopathy i ka mālama ʻana me nā lāʻau lapaʻau ʻē aʻe o kēia papa me ka hoʻohana pū ʻana i ka cyclosporine, nā fibrates, erythromycin, ka waikū nikolinidiko ma nā pākana hypolipidemic (ma mua o 1 g) a i nā lāʻau antifungal (azole derivatives). ʻOi aku ka nui o kēia mau lāʻau i ka CYP3A4 isoenzyme metabolism a me / a i ʻole lawe i nā mea i lawe i ka lāʻau. Ua ʻike ʻia ka cyenchrome CYP3A4 isoenzyme ka mahele nui isoenzyme i komo i ka biotransformation o atorvastatin. Ke koho ʻana i ka Liprimar ® me ka hui pū me nā fibrates, erythromycin, immunosuppressants, antifungal drug (azole derivatives) a i ʻole ka nikotinic acid i nā kūmole hypolipidemic, nā pōmaikaʻi i manaʻo ʻia a me kahi hiki ke mālama ʻia e mālama pono ʻia. Pono kiaʻi pinepine ʻia nā mea maʻi i mea e ʻike ai i ka ʻehaʻeha a nāwaliwali o ka naʻau, ma mua o nā mahina mua o ka mālama ʻana a i nā manawa he hoʻonui i nā dosis o kekahi lāʻau lapaʻau. Inā loaʻa, pono e noʻonoʻo pono i ka hui ʻana i ka hoʻohana ʻana i kēia mau lāʻau i ka hoʻohaʻahaʻa i ka wā mua a me ka mālama mālama ʻana. I kēlā mau kūlana, hiki ke hāpai ʻia ka hoʻonā wā maʻamau o ka hana CPK, ʻoiai ke pale ʻole ʻia kēlā me ke nānā ʻole i ka hoʻomohala ʻana i ka myopathy koʻikoʻi.

Ke hoʻohana nei i ka lāʻau lapaʻau Liprimar ®, e like me nā statins ʻē aʻe, nā līpona o ka rhabdomyolysis me ka hoʻomaʻamaʻa ʻole o ka pale ma muli o ka myoglobinuria. Inā hele mai nā hōʻailona o ka myopathy a aia paha ke pilikia o ka hiki ʻana o ka pūpū ma muli o ka rhabdomyolysis (no ka laʻana, he nui ke ahulau aʻeha, hypotension arterial, ʻeha nui, trauma, metabolic, endocrine a me nā electrolyte haunaele a me nā hana hoʻokele ʻole) oki.

Hoʻomaʻamaʻa ʻia nā mea maʻi e pono koke lākou e kūkā i ke kauka inā ʻaʻole i loaʻa ka ʻeha a i ʻole nā ​​nāwaliwali o ka naʻau, ʻoiai inā e hele pū lākou me ka malaise a me ka maʻi maʻi.

Hoʻokomo i ka hiki ke lawe i nā kaʻa a kāohi i nā mīkini

ʻAʻohe ʻikepili e pili ana i ka hopena o ka atorvastatin ma ka hiki ke kāhea i nā kaʻa a komo i nā hana e pili ana i nā hanana pōʻino e pono ai ka piʻi ʻana o ka nānā a me ka wikiwiki o ka hopena psychomotor.

Hoʻohana i ka wā hāpai a me ka lactation

ʻO controsed a Liprimar i ka wā hāpai.

Pono nā wahine o nā makahiki hānau hānau i nā ala kūpono o ka contraception i ka wā mālama. Hoʻopili ʻia ka hoʻohana ʻana o Liprimar i nā wahine o ka wā hānau keiki ʻaʻole ia e hoʻohana i nā ʻano kūpono o ke kūpaʻa.

Ua nānā ʻia nā hihia keu o ka kongenital anomalies ma hope o ka hoʻolaha ʻana i ka maʻi fetus i loko o ka ʻōpū ma hope o ka HMG-CoA reductase inhibitors (statins). Ua hōʻike nā noiʻi holoholona i nā hopena laʻala ma ka hana hānau. ʻO contrected Liprimar i ka wā lactation. ʻAʻole i ʻike ʻia inā excreted i ka atorvastatin i loko o ka waiū umauma. Inā pono e kuhikuhi i ka lāʻau lapaʻau i ka wā lactation, pono e ʻoki ʻia ka ʻōpū o ka pale ʻana i ka hopena o nā hanana ʻino i nā pēpē.

Ke keu

ʻAʻohe mea antidote kikoʻai no ka mālama ʻana i ka overdose me Liprimar. Ma ka hihia o kahi overdose, pono hōʻike ʻia kahi hōʻailona hōʻailona e pono. Pono e hana ʻia nā hoʻokolohua kūpono o ka ʻāʻī a nānā ʻia nā hana CPK. ʻO ka mea ikaika a hoʻopaʻa ʻia ka lāʻau i ka protein plasma, ʻaʻole pono ka hemodialysis.

Hoʻohui nūhou

Me ka hoʻomohala pinepine ʻana o Laprimar me ka cyclosporine, erythromycin, nā lāʻau antifungal mai ka hui azole a me nā derivatives waikawa fibroic, ʻoi ka ulu ʻana o ka hoʻoulu ʻana i ka myopathy nui hoʻonui.

Me ka hoʻohana pū ʻana o ka atorvastatin me nā cytochrome inhibitors (P450 3A4) i loko o ke kō koko, ke piʻi nei ke ʻano o ka hana ikaika ʻole i loli.

Me ka hana like me nā inducers o ka Penena P450 3A4 isoenzyme, antacids, a me cholestipol, nā kuʻina o ka plasma o ka hoʻōla ʻana me ka hoʻohaʻahaʻa ʻole o ka atorvastatin. Eia naʻe, eia kahi hopena i hoʻopiʻi ʻia ai he lipid-lowing.

Ke hui pū ʻia me nā contraceptives waha e loaʻa ana ka ethinyl estradiol a me ka norethindrone, hoʻonui ʻia ko lākou ʻimi (AUC) ma 20-30%.

Pilikia ka pehu

E like me ka hoʻohana ʻana o nā lāʻau lapaʻau lipid-haʻahaʻa o kēia papa, me ka hoʻohana ʻana i ka lāʻau Liprimar, he hoʻonui haʻahaʻa (ʻoi aku ʻo 3 mau manawa i hoʻohālikelike ʻia me VGN) o ka hana o nā transaminases hepatic AST a me ALT. ʻO ka hoʻonui pinepine mau i ka hana serum o nā transaminases hepatic (ʻoi aku ma mua o 3 mau manawa i hoʻohālikelike ʻia me VGN) i nānā ʻia ma 0.7% o nā mea maʻi e loaʻa iā Liprimar. ʻO ka pinepine o nā loli i ka wā e hoʻohana ai i ka lāʻau lapaʻau ma nā inika o 10 mg, 20 mg, 40 mg a me 80 mg o 0.2%, 0.2%, 0.6% a me 2.3%, kēlā me kēia. I ka piʻi pinepine ʻana o ka hana hepatic transaminase maʻamau ʻaʻole i mālama ʻia e ka jaundice a i ʻole nā ​​hōʻike olakino ʻē aʻe. Me ka hoʻohaʻahaʻa ʻana i ka wai o Liprimar, ka wā ʻole a i ʻole piha i ka hōʻino ʻana i ka lāʻau, hoʻihoʻi ka hana o nā transaminases hepatic i kona pae mua. Hoʻomau ka hapa nui o nā poʻe maʻi e lawe i ka Liprimar i kahi emi iki me ka ʻole o kekahi hopena maʻi.

Ma mua o ka hoʻomaka, 6 mau hebedoma a me 12 mau pule ma hope o ka hoʻomaka ʻana o ka lāʻau lapaʻau a ma hope o ka hoʻonui ʻana i ka nui o ka nui, pono ia e nānā i nā ʻōnaehana hana pili. E nānā pū ʻia ka hana naʻau inā ʻike ʻia nā hōʻailona koʻikoʻi o ka hōʻeha o ka puʻuwai. I ka nui o ka hoʻonui ʻana i nā hana o ka transaminases hepatic, pono e nānā ʻia kā lākou hana a hiki i ka hoʻonui ʻia. Inā hoʻonui ka hoʻonui i ka hana o AST a i kahi ALT ma mua o 3 mau manawa i hoʻohālikelike ʻia me VGN e hoʻomau nei, e pono ana e hōʻemi i ka hopena a i ʻole ke kahuli ʻana iā Liprimar.

Pono e hoʻohana ʻia ka liprimar me ka makaʻala i nā mea maʻi e hoʻopau i nā nui o ka waiʻona a me / a i ʻole kahi moʻolelo o ka maʻi o ka ate. ʻO ka maʻi maʻi o ka ate a i ʻole mau loa ka hana o nā transaminases hepatic o ke kaila o ka puna kuʻuna o kahi kūmole he contraindication i ka hoʻohana ʻana o Liprimar.

Hoʻopau i nā io uaua o ka pōkole

Ua hoʻomaopopo ʻia ʻo Myalgia i nā maʻi e loaʻa ana iā Liprimar. Pono e noʻonoʻo ʻia i ka maʻi myopathy i loko o nā mea maʻi me ka hoʻolule i ka myalgia, ʻehaʻeha nā palupalu a i ʻole nāwaliwali a me / a me ke ʻano nui o ka hana KFK (ʻoi aku ma mua o 10 mau manawa i hoʻohālikelike ʻia me VGN). Pono e hoʻoneʻe ʻia ka liprimar e hoʻonui ʻia i kahi hana CPK, ma ke alo o ka myopathy i hoʻopaʻa ʻia a i ʻole. ʻO ka loaʻa o ka myopathy i ka wā e mālama ʻia me nā lāʻau lapaʻau hou o kēia papa me ka hoʻohana pinepine ʻana i nā mea paʻa ikaika o ka isoenzyme CYP3A (no ka laʻana, ka cyclosporine, telithromycin, clarithromycin, delavirdine, styripentol, ketoconazole, voriconazole, itraconazole, posaconazolein, ravira darunavir), gemfibrozil a i ʻole nā ​​fibrates, boceprevir, erythromycin, acid acidotinic i nā lipid e hoʻohaʻahaʻa i ka wai (ʻoi aku ma mua o 1 g / lā), ezetimibe, nā mea āpau azole antifungal, colchicine, telaprevir, boceprevir, a i ʻole kekahi hui o tipranavir / ritonavir. ʻOi aku ka nui o kēia mau lāʻau i ka CYP3A4 isoenzyme metabolism a me / a i ʻole lawe i nā mea i lawe i ka lāʻau. Ua ʻike ʻia ka cyenchrome CYP3A4 isoenzyme ka mahele nui isoenzyme i komo i ka biotransformation o atorvastatin. Kahi i ka Liprimar i hui pū me nā fibrates, erythromycin, immunosuppressants, antifungal drug (azole derivatives) a i ka hopena nikotinic ma nā ʻaina hypolipidemic (ʻoi aku ma mua o 1 g / lā), pono ke kumu kūpono i manaʻo ʻia a me nā hopena e hiki ke mālama ʻia. Pono kiaʻi pinepine ʻia nā mea maʻi i mea e ʻike ai i ka ʻehaʻeha a nāwaliwali o ka naʻau, ma mua o nā mahina mua o ka mālama ʻana a i nā manawa he hoʻonui i nā dosis o kekahi lāʻau lapaʻau. Inā loaʻa, pono e noʻonoʻo pono i ka hui ʻana i ka hoʻohana ʻana i kēia mau lāʻau i ka hoʻohaʻahaʻa i ka wā mua a me ka mālama mālama ʻana. ʻAʻole hoʻolako ʻia ka hoʻohana pinepine ʻana o ka atorvastatin a me ka waikawa fusidic; no laila, ʻoi aku ka haʻalele ʻana o ka atorvastatin i ka wā o ka mālama ʻana me ka waikawa fusidic. I kēlā mau kūlana, hiki ke hāpai ʻia ka hoʻonā wā maʻamau o ka hana CPK, ʻoiai ke pale ʻole ʻia kēlā me ke nānā ʻole i ka hoʻomohala ʻana i ka myopathy koʻikoʻi.

Ma mua o ka hoʻomaʻamaʻa

Pono e hoʻohana ʻia ka liprimar me ka makaʻala i nā mea maʻi me nā mea e ʻike mua ana i ka hoʻomohala ʻana o ka rhabdomyolysis. Pono e kāohi ʻia ka hana CPK i kēia mau hihia aʻe ma mua o ka hoʻomaka ʻana i ka therapy atorvastatin:

• huakaʻi renal function,
• hypothyroidism
• mau hoʻoili kino ʻōwili i ka mōʻaukala a i ʻole ka moʻolelo ʻohana,
• i hoʻihoʻi mua i ka hopena toxic o HMG-CoA reductase inhibitors (statins) a i ʻole ka fibrates ma ka io o ka ʻiʻo,
• ka mōʻaukala o ka pūpū a me / a me nā mea maʻi e ʻai i nā nui waiʻona,
• i nā mea maʻi i ʻoi aku o 70 mau makahiki, pono e nānā ʻia ka pono, e nānā ka ʻike, aia ka mea i loaʻa i kēia mau maʻi nā mea i manaʻo ʻia i ka hoʻomohala ʻana o ka rhabdomyolysis,
• kahi e hāpai ai i ka hoʻonui ʻia ʻana o ka kukuna plasma o atorvastatin, e like me ka hoʻopili ʻana me nā lāʻau ʻē aʻe. I kēlā mau kūlana, pono e loiloi ʻia ka hopena o ka pilikia / pōmaikaʻi a pono e mālama ʻia ke nānā ʻana i ka maʻi o ka maʻi. I ka hihia o ka hoʻonui nui ʻana i ka hana CPK (ʻoi aku ma mua o 5 mau manawa i ʻoi aku ma mua o VGN), ʻaʻole pono e hoʻomaka ka lāʻau atorvastatin.

Ke hoʻohana nei i ka lālani Liprimar, a me nā poʻe ʻē aʻe i paʻa aku ka hoʻemi hou ʻia o HMG-CoA reductase, nā hihia līnika o ka rhabdomyolysis me ka hiki ʻole o ka hana renal ka hopena no ka myoglobinuria. Hiki i ke kumu pilikia no ka rhabdomyolysis kahi mua i hana ʻole ʻia i mua o ka hana. Pono e hāʻawi ʻia kēlā mau maʻi e kiaʻi me ka mālama pono ʻana i ka mokuʻāina o ka ʻōnaehana musculoskeletal. Inā hele mai nā hōʻailona o ka myopathy a i ʻole nā ​​mea kūpono no ka hoʻomohala ʻana i ka ʻeha ʻole ma muli o ka rhabdomyolysis (no ka laʻana, ka maʻi nui ʻana o ka maʻi, ka hypotension arterial, nui o nā hōʻeha, nā hōʻeha, metabolic, endocrine a me ka wai-electrolyte haunaele, hana hoʻomāino ʻole ʻia), Liprimar hoʻopau loa.

Hoʻomaʻamaʻa ʻia nā mea maʻi e pono koke lākou e kūkā i ke kauka inā ʻaʻole i loaʻa ka ʻeha a i ʻole nā ​​nāwaliwali o ka naʻau, inā ua hele pū lākou me ka malaise a me ka maʻi maʻi.

Hoʻomaʻamaʻa aku ka Stroke ma o ka hōʻemi ʻana i ka Cholesterol Active

I kahi hōʻike retrospective o nā subtypes stroke i loko o nā poʻe maʻi me ka maʻi ʻalopona coronary, ka mea i loaʻa iā ia kahi hōʻeha a i ʻole ka hōʻea ʻana i ka ischemic attack, ma ka hana mua ka mea i loaʻa i ka atorvastatin ma ke kūkaʻi o 80 mg, he kūlana kiʻekiʻe o ka hemorrhagic stroke i hoʻomaopopo ʻia me ka poʻe maʻi e loaʻa ana i ka placebo. ʻO ka piʻi nui e ʻike ʻia i ka poʻe maʻi me ka mōʻaukala o ka hemorrhagic stroke a i ʻole ka lacunar infarction i ka hoʻomaka ʻana o ke kula. Ma kēia pūʻulu o nā mea maʻi, ʻo ka loiloi o ka pōmaikaʻi / a i ka wā e lawe ai i ka atorvastatin i kahi mahele ʻo 80 mg ʻaʻole i wehewehe maikaʻi ʻia, ma kēia ʻano, ma mua o ka hoʻomaka ʻana i ka maʻi, ka hopena hiki ke hoʻomohala i ka ʻōpū hemorrhagic i kēia mau mea maʻi e loiloi maikaʻi ʻia.

Ma hope o kahi loiloi kūikawā o kahi noiʻi hauoli e pili ana i ka poʻe 4731 nā mea maʻi me ka maʻi ʻaluna coronary nona ka hōʻeha a i ka weliweli ischemic attack (TIA) i loko o nā mahina 6 mau i hala i kuhikuhi ʻia ma atorvastatin 80 mg / lā, he kūlana kiʻekiʻe o nā ʻeha hemorrhagic i ka hui atorvastatin o 80 mg i hōʻike ʻia ka hui plasebo (55 ma ka atorvastatin hui kūlike 33 i ka hui plasebo). ʻO ka poʻe maʻi me ka ʻōpū hemorrhagic i ka manawa o ke komo ʻana i ke aʻo ʻana he kiʻekiʻe kiʻekiʻe ka nui no ka mau hou ʻana i ka ʻōpū hemorrhagic (7 ma ka hui atorvastatin e kūʻē 2 i ka hui plasebo). Eia naʻe, nā poʻe maʻi e loaʻa ana i ka atorvastatin 80 mg / lā he mau liʻiliʻi iki o nā hōʻeha o kekahi ʻano (265 kūlike 311) a me nā hanana cardiovascular liʻiliʻi (123 a 204).

Naʻi maʻi mellitus

Hōʻike kekahi mau data e hiki i ka HMG-CoA reductase inhibitors (statins), me kahi papa, hiki ke alakaʻi i ka hoʻonui ʻana i ka glucose glucose plasma, a i kekahi mau maʻi me ka ʻeha o ka hoʻomohala ʻana i ka maʻi mellitus, kahi kūlana o ka hyperglycemia e ulu i makemake ʻia e hoʻoponopono ʻia e like me ka maʻi mellitus. Eia naʻe, ʻaʻole i keu kēia pilikia i ka pono o ka mālama ʻana me ka HMG-CoA reductase inhibitors (statins) i nā ʻōlelo o nā hopena vascular, no laila ʻaʻole hiki kēia ke kumu no ka hoʻopau ʻana i ka lāʻau. ʻO ka poʻe maʻi e pili ana i ka hui o ka mea pilikia (ka hoʻoku ʻana o ke kaila o ke koko mai 5.6 a 6.9 mmol / l, BMI> 30 kg / m, i hoʻonui ʻia i ka plasma triglycerides, a me ke ʻano o ka haole) ma lalo o ka mālama kiaʻi ʻana, me ka nānā ʻana i nā ʻōnaehana biochemical param. e like me nā ʻōlelo loiloi kūloko.

ʻO ka maʻi māmā interstitial

I ka wā o ka mālamaʻana me kekahi mau HMG-CoA reductase inhibitors (statins), ka mea i ka wā e hoʻolako nei i nā manawa lōʻihi, ua hōʻike ʻia nā hihia o ka maʻi interstitial lung. ʻO ka dyspnea, kahi pākē hua ʻole, a me kahi hōʻemi i ka nui o ke olakino (ʻoi aku ka momona, ke kaumaha ʻana o ke kaupaona ʻana, a me ke ʻano o ka maʻi paha). Inā kānalua ka mea maʻi i ka maʻi māmā interstitial, pono e hoʻokaʻawale ke ʻano atorvastatin.

Ka hana Endocrine

Ke hoʻohana nei i nā inhibitors o ka HMG-CoA reductase (statins), me ka atorvastatin, ua loaʻa nā hihia o ka hemoglobin glycosylated (HbA1) a me ka hoʻomakeke ʻana i ka glucose glucose glucose. Eia naʻe, ʻoi aku ka liʻiliʻi o ka hopena o ka hyperglycemia ma mua o ke kaemi o ka hōʻemi ʻana i ka hopena o ka hopena vascular aʻo ka lawe ʻana i ka HMG-CoA reductase inhibitors (statins).

Hoʻopilikia i ka hiki ke hoʻokau i nā kaʻa

ʻAʻohe ʻikepili e pili ana i ka hopena o Liprimar i ka hiki ke hoʻokau i nā kaʻa a komo i nā hana e hana ʻino ʻia e pono ai ka piʻi ʻana o ka nānā a me ka wikiwiki o ka hopena psychomotor. Akā, ʻoiai ke hiki i ka hoʻomohala ʻana i ka dizziness, e akahele ʻia i kēia mau hana

Nā kūlana mālama

Store ma kahi maloʻo loa a pouli hoʻi, i waho o ka hiki o nā keiki, i ke ʻano wela ʻole ʻoi aku ʻo 25 C. Papa ola 3 mau makahiki.Ma hope o kēia manawa, pāpā ʻia ka hoʻohana ʻana i ka lāʻau.

ʻO ke kumukūʻai kumukūʻai o 30 mau papa o Liprimar 20 mg i mau lāʻau lapaʻau ma Moscow he 420-460 rubles.

ʻO nā mea hoʻohālike liprimar no ka hana therapeutic i mea hoʻohana i nā lāʻau.